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Introduction: Approximately 50% of lung cancer patients with 
 epidermal growth factor receptor (EGFR)-mutations (deletion in 
exon 19 or L858R) who develop acquired resistance to EGFR tyro-
sine kinase inhibitors (TKIs) reportedly carry a secondary EGFR 
T790M mutation. This mutation has been suggested to be present 
in tumor cells before EGFR-TKI treatment in a small population 
of individuals. Here, we use a highly sensitive colony hybridization 
technique in an attempt to evaluate the actual incidence of T790M in 
pretreatment tumor specimens.
Methods: DNA was extracted from surgically resected tumor tis-
sues of 38 patients with the EGFR mutation and examined for the 
presence of T790M, using a standard polymerase chain reaction 
based method followed by a modified colony hybridization (CH) 
technique with an analytical sensitivity of approximately 0.01%. 
Associations between the T790M status and clinical characteris-
tics including time to treatment failure (TTF) for EGFR-TKI were 
evaluated.
Results: The T790M mutation analysis of the specimens from the 38 
patients detected 30 mutants (79%). The median TTF was 9 months 
for the patients with pretreatment T790M and 7 months for the patients 
without the T790M mutation (p = 0.44). When the patients with T790M 
were divided into strongly positive and modestly positive subgroups in 
terms of the frequency of positive signals observed using CH technique, 
the 7 patients with strong positivity had a TTF that was significantly 
longer than that of the 8 patients without T790M (p = 0.0097) and of the 
23 patients with modest positivity (p = 0.0019).
Conclusions: Our highly sensitive CH method showed that a sub-
group of non–small-cell lung cancer patients with the EGFR 
mutation harbored the rare T790M allele before EGFR-TKI treatment. 
A high proportion of T790M allele may define a clinical subset with 
a relatively favorable prognosis.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
receptor mutation, Colony hybridization.
(J Thorac Oncol. 2012;7: 1640–1644)
Non–small cell lung cancer (NSCLC) patients with an activating mutation within the tyrosine kinase domain 
of the epidermal growth factor receptor (EGFR) respond dra-
matically to EGFR tyrosine kinase inhibitors (TKIs).1,2 The 
common activating mutations include in-frame deletions in 
exon 19 (dels) and a point mutation in exon 21 (L858R), all of 
which lead to the sustained activity of EGFR tyrosine kinase. 
Unfortunately, almost all patients with these activating muta-
tions eventually develop acquired resistance while receiving 
EGFR-TKI treatment.3,4 A secondary mutation in exon 20 
(T790M) is observed in approximately 50% of such cases.5,6 
The T790M mutation alters the relative affinity of the mutant 
receptor in favor of adenosine triphosphate (ATP), abrogating 
the effect of EGFR-TKIs.7
The mechanism by which the secondary mutation 
emerges remains unclear. One possibility is that a minor 
population of tumor cells with the T790M mutation exists 
among the pretreatment tumor cells. Indeed, the T790M muta-
tion has been detected in a few pretreatment tumor samples.8,9 
However, the frequency of T790M mutations in these pre-
treatment samples was insufficient to explain why the T790M 
mutation occurs in approximately half the EGFR-TKI–resis-
tant cases. We hypothesized that the actual population of 
tumor cells harboring the T790M mutation may be below the 
detection limit and may be assessable using a more sensitive 
assay system.
Here, we report the development of a highly sensitive 
colony hybridization (CH) method that detects low levels 
of the T790M mutation. We used this method to assess the 
T790M mutation in surgically resected tumor samples from 
NSCLC patients to resolve: (1) the frequency of tumor 
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samples carrying the T790M mutation before EGFR-TKI 
treatment; and (2) its association with the clinical outcome.
PATIENTS AND METHODS
Patients and Sample Collection
Primary tumor samples were collected from NSCLC 
patients who underwent potentially curative pulmonary resec-
tion at the Department of Thoracic Surgery, Aichi Cancer 
Center Hospital, Japan, between March 1997 and January 
2007. Informed consent was obtained from each patient before 
the operation. All the tumor samples were snap-frozen and 
stored at −80°C. For each specimen, the frozen sections were 
thawed and stained with hematoxylin and eosin to examine 
the proportion of tumor cells in the tissue. The genomic DNA 
contained at least 20% of the tumor content in our cohort. To 
extract the genomic DNA, the tissues were incubated with 1 × 
(polymerase chain reaction) PCR buffer containing 100 μg/mL 
proteinase K for 1 hour at 54°C. Next, the solution was incubated 
for 3 minutes at 95°C. As a preliminary experiment, we had pre-
viously assessed the presence of EGFR mutations in exons 18 to 
21 using a direct sequencing analysis with previously described 
primers and protocols.10 Patients with EGFR mutations were 
enrolled in the study. Patients who had received EGFR-TKI 
treatment before surgery were not eligible. The complete clinical 
data records including age, sex, pathological diagnosis, clinical 
stage, and dates of surgery and relapse were obtained from each 
patient’s medical records and were reviewed by the physicians.
Scorpion Amplification Refractory 
Mutation System Assay
The Therascreen EGFR Mutation Kit (QIAGEN, 
Tokyo, Japan), which is designed to detect 29 types of EGFR 
mutations including T790M, was used for the Scorpion 
Amplification Refractory Mutation System (SARMS) assay, 
according to the manufacturer’s instructions.
Colony Hybridization Assay
A CH assay was performed to detect the T790M EGFR 
mutation according to a previously described method, 
with some modifications.11 Exon 20 of the EGFR gene was 
amplified for each DNA sample with a forward primer, 
5ʹ–CCATGAGTACGTATTTTGAAACTC–3ʹ (EGFR_Ex20_f) 
and a reverse primer, 5ʹ–CATATCCCCATGGCAAACTCTTGC–3ʹ 
(EGFR_Ex20_r) using PrimeSTAR® HotStart DNA Polymerase 
(Takara Bio Inc., Ohtsu, Japan). The amplified 458 bp PCR 
fragment was cloned into a TOPO blunt cloning vector 
(Invitrogen, Carlsbad, CA). The resultant plasmid was used to 
transform Escherichia coli (TOP10) cells, which were then 
plated on Luria Broth-agar containing kanamycin. Blue/white 
selection using 40 mg/mL X-gal (Wako, Osaka, Japan) was 
performed to subtract the number of cells harboring an empty 
vector from the total number. The number of white colonies 
was used as a parameter to calculate the proportion of T790M 
colonies. After overnight incubation, the colonies (typically 
1000–5000 colonies per plate) were transferred to a Hybond-N+ 
membrane (GE Healthcare, Buckinghamshire, United 
Kingdom) and hybridized using oligonucleotide probes 
labeled with γ-32P-ATP. The sequences of the oligonucleotide 
probes were 5ʹ–CTCATCACGCAGCTCATGCC–3ʹ for the 
wild-type product and 5ʹ–CTCATCATGCAGCTCATGCC–3ʹ 
for T790M (the altered nucleotide is underlined). The mem-
brane was incubated for 16 hours at 37°C in hybridization 
solution containing 6 × saline-sodium citrate, 0.5% sodium 
dodecyl sulphate, 5 × Denhardt’s solution, and 100 μg/mL of 
salmon sperm DNA, to which 8 × 105 count per minute/mL of 
γ-32P-ATP-labeled probe had been added. After hybridization, 
the membranes were washed twice for 30 minutes at 55 °C in 
6 × saline-sodium citrate and exposed to film. The black dots 
visualized on the film were judged as positive colonies. An 
assay was performed to evaluate positive cases until at least 
two independent positive colonies were obtained. Cases in 
which no signal was screened among 10,000 white colonies 
were judged as negative cases. To confirm the results, the posi-
tive colonies were selected to extract the plasmids and the 
inserted DNA was sequenced using the EGFR_Ex20_f primer.
To assess the sensitivity and specificity of both the wild-
type and the T790M oligonucleotide probes, plasmids contain-
ing wild-type and T790M sequences were made as described 
above, using DNAs extracted from A549 and H1975 cell lines, 
respectively, as templates. Five control DNA solutions (#1–5) 
were prepared at different ratios of T790M to wild-type plasmid 
DNA as follows: #1, 0 %; #2, 100 %; #3, 1%; #4, 0.1%; #5, 
0.01%. For each solution, the plasmid DNA was adjusted to 5 pg 
(approximately 1,000,000 copy equivalent)/μL.
Statistical Analyses
The Fisher’s exact test was used to assess the relation-
ship between the T790M mutation status and different char-
acteristics, including sex and the primary mutation status. 
The Mann-Whitney test was used to assess the relationship 
between the T790M mutation status and age. Time to treat-
ment failure (TTF) was defined as the interval between the 
initiation of EGFR-TKI treatment until the documentation of 
resistance to EGFR-TKI therapy, relapse, or death after hav-
ing achieved a partial response or complete response. The sur-
vival curves were calculated according to the Kaplan–Meier 
method, and comparisons were performed using StatView 
software (version 5; SAS Institute, Cary, NC). p Value less 
than 0.05 was considered statistically significant.
RESULTS
Assessment of CH Assay Sensitivity
We assessed the sensitivity and specificity of both the 
wild-type and T790M oligonucleotide probes using control 
DNA solutions (#1–5). When the probe specific for the wild-type 
sequence was used, many dots were visualized for the control 
DNA solution #1 (wild-type alone), whereas no unambiguous 
dots were observed for control DNA solution #2 (T790M alone) 
(Fig. 1A). Meanwhile, the T790M probe produced no visible 
dots for control DNA solution #1 whereas many dots were 
vividly visualized for control DNA solution #2 (Fig. 1B). The 
results showed that these probes, even if their sequences differed 
from each other by only one base, specifically hybridized the 
complementary clones under the reaction conditions used. We 
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additionally performed sensitivity assays using the serially 
diluted T790M DNA solutions (#3–5) as shown in Fig. 1C, D, 
and E. Many dots indicating the wild-type clones and a small 
number of dots indicating the T790M clones were observed in 
each case. The positive signal ratios for T790M in each DNA 
solution were as follows: for solution #3, three of 260 white 
colonies (1.15%); for solution #4, two of 1760 white colonies 
(0.11%); and for solution #5, two of 10,000 white colonies 
(0.02%). These ratios reflect the actual proportions of T790M 
clones included in each solution: #3, 1 %; #4, 0.1 %; and #5, 
0.01 %. Direct sequencing was performed for DNAs isolated 
from several visualized colonies to confirm their positivity (data 
not shown).
Patient Characteristics
Thirty-eight patients with EGFR mutation were enrolled 
in this study (Table 1). The histological type in all the patients 
was adenocarcinoma. The primary mutation status was pre-
assayed for each patient, using direct sequencing. Twenty-
two patients (57.9 %) had a deletional mutation in exon 19, 
two patients (5.3 %) had a point mutation in exon 18 (n = 1, 
G719A; n = 1, G719C), one patient (2.6 %) had a 6 bp inser-
tion in exon 19 and 13 (34.2 %) had a point mutation in exon 
21 (n = 12, L858R; n = 1, L858R + E709G). All patients had 
prospectively received treatment with gefitinib.
Detection of EGFR T790M in Tumor Tissues
The EGFR mutations detected in the tumor samples 
are summarized in Table 1. The SARMS assay detected no 
T790M mutation in any of the patients. Using the CH assay, 
however, the T790M mutation was found in 30 of the 38 
patients (78.9%). The positive colonies detected for patient 
no. 27 are shown as an example in Supplementary Figure 1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A326). The mutation was confirmed by direct sequencing in 
at least two colonies per patient. Among the 30 positive cases, 
the positive clones were present at a low ratio to the total 
FIGURE 1.  Representative allele-specific oligonucleotide 
colony hybridization for the quantitation of the T790M  
mutation. A and B, Hybridizing clones (black dots) are shown 
for control DNA solutions #1 (wild) and #2 (T790M) using  
(A) the wild-type probe and (B) the T790M probe. C, D, and 
E, Colonies for control DNA solutions #3 (1 % T790M), #4 
(0.1% T790M), and #5 (0.01 % T790M) were hybridized 
with both wild type- and T790M- specific oligonucleotides.
TABLE 1.  Detection of EGFR T790M Mutation in NSCLCs 
with Activating Mutation
No. Age Sex Stage
Primary  
Mutation
T790M detection
SARMS CH
T790M/Total 
Colonies (%)
1 80 F L858R - + 22/5,112 (0.43)
2 68 F Del - + 6/5,531 (0.11)
3 59 F L858R - + 2/4,987 (0.04)
4 68 M L858R - + 2/4,313 (0.05)
5 69 F Del - + 3/1,993 (0.15)
6 61 M L858R - + 25/2,788 (0.90)
7 52 M Del - + 33/5,269 (0.63)
8 69 F Del - + 2/2,278 (0.09)
9 59 M L858R - + 3/4,245 (0.07)
10 79 F Del - + 2/4,832 (0.04)
11 71 F L858R - + 12/2,294 (0.52)
12 51 F L858R - + 31/1,702 (1.82)
13 73 F Del - + 8/1,298 (0.62)
14 66 F Del - + 12/2,359 (0.51)
15 52 F Del - + 6/5,021 (0.12)
16 63 F L858R - + 20/1,805 (1.11)
17 53 F L858R - + 2/1,465 (0.14)
18 68 F L858R - + 3/3,810 (0.08)
19 61 M G719C - + 2/1,990 (0.10)
20 78 M G719A - + 3/1,482 (0.20)
21 74 M Del - + 2/2,277 (0.09)
22 67 M Del - + 2/6,032 (0.03)
23 64 F Del - + 6/3,998 (0.15)
24 57 F L858R - + 3/5,756 (0.05)
25 50 F L858R - + 3/5,215 (0.06)
26 71 M Del - + 5/2,774 (0.18)
27 36 M Del - + 2/9,443 (0.02)
28 61 F Del - + 2/4,308 (0.05)
29 80 M Del - + 4/5,490 (0.07)
30 62 F Del - + 3/3,541 (0.08)
31 56 M Del - - 0/10,823 (0)
32 50 F L858R - - 0/10,456 (0)
33 45 M Del - - 0/11,642 (0)
34 70 F Del - - 0/12,309 (0)
35 64 F Del - - 0/11,769 (0)
36 63 F Ins - - 0/12,013 (0)
37 61 M Del - - 0/12,468 (0)
38 54 M Del - - 0/12,233 (0)
SARMS, Scorpion Amplification Refractory Mutation System; CH, colony 
hybridization method; Del, deletional mutations in exon 19; Ins, insertional mutation 
in exon 19. 
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colony number (0.02%–1.82%). No relationships between 
the T790M mutation status and other clinical characteristics 
including age, sex, and primary mutation status were detected 
(Table 2).
TTF Survival Analysis
In our cohort of 38 patients, the median TTF in patients 
with the T790M mutation (n = 30) was not statistically dif-
ferent from that in the patients without the mutation (n = 8) 
(p = 0.44), being 10 months and 8 months, respectively (Fig. 2A). 
When the patients were subdivided into three groups based 
on the detection rate for T790M colonies (nil: 0 %, n = 7; low: 
0%–0.5 %, n = 23; and high: ≥ 0.5 %, n = 8), the median TTF 
for the patients with a high proportion was 41 months, which 
was significantly longer than that for the low-proportion group 
(7 months, p = 0.0019) or the nil-proportion group (7 months, 
p = 0.0097) (Fig. 2B). We also compared the TTF among the 
patients according to their mutation statuses (exon 19 del, 
n = 22; L858R, n = 13; and others, n = 3) and found no statisti-
cal differences (Supplementary Fig. 2, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A327).
DISCUSSION
Our findings have shown that the T790M mutation is 
detectable in tumor tissues obtained from EGFR-TKI naive 
patients and that the CH is a useful method for detecting the 
T790M mutation. Through this method, we identified the 
T790M mutation in 30 of 38 untreated samples (79%), a much 
higher proportion of T790M mutant tumors than previously 
reported.8,9 We initially used SARMS, a highly sensitive detec-
tion method, but the EGFR T790M mutation was not detected 
in any of the untreated samples examined in the present cohort. 
A possible reason for the higher proportion of T790M in this 
study may be the high sensitivity of our CH method. This 
method enables a very large number of colonies carrying dif-
ferent hybrid plasmids to be rapidly screened for a specified 
DNA sequence.11,12 The sensitivity at which a single mutant 
genomic clone can be detected among normal clones has been 
estimated to be 1:1000 to 1:10,000.13 Indeed, we detected posi-
tive signals when a mutant genomic clone was diluted with 
normal clone to 0.01%. Moreover, unlike other sensitive assays 
such as SARMS, the CH method produces no false-positive 
results, because colonies of interest can be determined to 
be either positive or negative by sequencing. Given that the 
T790M mutation occurs in cis with the activating mutation 
(dels or L858R) on the same allele,6 the exact incidence rate 
of the T790M mutation may be corrected by the frequency of 
the activating mutations, which may vary among the patients.
This is the first report showing a positive correlation 
between the presence of T790M before EGFR-TKI treatment 
and patient outcome. To our surprise, the median TTF for seven 
patients with a high proportion (≥ 0.5%) was 41 months, which 
was significantly longer than that for 23 patients with a low 
proportion (0%–0.5 %, 7 months) and eight patients with a nil 
proportion (7 months) (Fig. 2B). This data suggested that the 
abundance, but not the presence, of T790M in untreated cancer 
cells impacted the benefits of EGFR-TKI treatment. This result 
was unexpected, because the outcome of the patients with an 
activating mutation who acquire a resistance mutation is likely 
to worsen.8,14,15 The results of a study by Oxnard et al.16 may 
support our findings. They showed that EGFR-TKI resistant 
patients with T790M identified in rebiopsy specimens had a 
relatively favorable prognosis compared with patients without 
the T790M mutation.16 In a basic research study, the acquisition 
of T790M was associated with a slowdown in tumor growth,6 
FIGURE 2. Kaplan–Meier curves for time to treatment failure 
(TTF) are shown for patients according to (A) their T790M 
status, and (B) the proportion of T790M colonies detected in 
surgically resected, pre-TKI treatment samples.
TABLE 2. Patient Characteristics and T790M Mutation Status
T790M Status
Positive Negative (P value)
Sex 0.69
Male 16 12 4
Female 24 20 4
Age 0.46
≥60 25 21 4
>60 13 9 4
Primary mutation 0.29
Del 22 6 16
L858R 13 1 12
Others 3 1 2
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possibly explaining the longer TTF among the patients with a 
high ratio of T790M. Another explanation is that the patients 
who are devoid of T790M may acquire some other mechanism 
of resistance, leading to their poorer prognosis.16
NSCLC cells harboring the T790M mutation may be 
present before EGFR-TKI exposure as a small drug-tolerant 
subpopulation in cells with activating mutations.17 The propor-
tion of T790M mutant alleles may increase gradually during 
treatment, eventually becoming present at an easily detectable 
level in half of the patients at the time of clinical progression 
to EGFR-TKI resistance.
In conclusion, using a highly sensitive CH method, we 
showed that a subgroup of NSCLC patients with the EGFR 
mutation harbored the rare T790M allele before EGFR-TKI 
treatment. A high proportion of T790M alleles may define a 
clinical subset with a relatively favorable prognosis.
ACKNOWLEDGMENT
We thank Kusuo Tatsumi, Yukiko Yamamoto, and 
Norinaga Kakishita for support with the radioisotope 
work; Yoshihiro Mine for the sequencing work; and Tomoko 
Kitayama for technical support.
REFERENCES
 1. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell 
lung cancer harbouring mutations of the epidermal growth factor recep-
tor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 
2010;11:121–128.
 2. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study 
Group. Gefitinib or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. N Engl J Med 2010;362:2380–2388.
 3. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. 
Screening for epidermal growth factor receptor mutations in lung cancer. 
N Engl J Med 2009;361:958–967.
 4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel 
in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
 5. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance 
of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–792.
 6. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-
mutant non-small cell lung cancer with evolutionary cancer modeling. Sci 
Transl Med 2011;3:90ra59.
 7. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR 
kinase causes drug resistance by increasing the affinity for ATP. Proc Natl 
Acad Sci USA 2008;105:2070–2075.
 8. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations 
in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359: 
366–377.
 9. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M muta-
tion and BRCA1 mRNA expression in erlotinib-treated advanced non-
small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 
2011;17:1160–1168.
 10. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. 
Mutations of the epidermal growth factor receptor gene in lung cancer: 
biological and clinical implications. Cancer Res 2004;64:8919–8923.
 11. De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K. False 
positive results in chimeraplasty for von Willebrand Disease. Thromb Res 
2007;119:93–104.
 12. Saitoh M, Niijima M, Takiguchi Y, et al. An early event of EGFR muta-
tion in pleomorphic carcinoma of the lung. Int J Clin Oncol 2011;16: 
770–773.
 13. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. Detection of 
oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer 
Res 1994;54:1634–1637.
 14. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor 
receptor gene T790M mutation as a minor clone in non-small cell lung 
cancer. Cancer Res 2006;66:7854–7858.
 15. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor 
receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase 
inhibitor response duration in patients with non-small-cell lung cancer. J 
Clin Oncol 2012;30:433–440.
 16. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR 
tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natu-
ral history of patients with tumors harboring the T790M mutation. Clin 
Cancer Res 2011;17:1616–1622.
 17. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-
tolerant state in cancer cell subpopulations. Cell 2010;141:69–80.
